Developer docs
API playgroundTry for free, no card

Search company profiles

StemCord

Full company profile

uuid003j74h

Namestring
StemCord
Legal namestring
STEMCORD SG PHILS. CORPORATION
Websiteurl
stemcord.com.ph
Company typeenum
Private
Founded yearint
2002
Descriptiontext

StemCord is a privately-held, autologous cord blood bank incorporated in March 2002 and headquartered in Singapore, with regional operations in the Philippines (opened 2020) and Indonesia. It collects, processes, and cryopreserves umbilical cord blood containing haemopoietic stem cells (HSCs) and, since the 2015 Stem Med partnership, mesenchymal stem cells (MSCs) cultured from cord tissue using its proprietary CultureFIRST method, which the company claims yields approximately 8x more viable cells than traditional frozen-tissue extraction. Samples are processed in an ISO Class 5 clean room, coded under the ISBT 128 standard, and stored in vapour-phase liquid nitrogen at -180 deg C or colder across two separate cryo bags at two distinct laboratory locations in Singapore. The company was founded and is led by practising haematologists, medical oncologists, and a nephrologist with direct bone-marrow and stem-cell transplantation programme experience at Singapore General Hospital and National University Hospital.

The commercial model is direct-to-consumer, targeting expectant parents in the third trimester of pregnancy (around 28-32 weeks). Customers enrol through sales consultants at baby and parenting fairs (e.g. Momzilla Fair, Edamama New Mama Expo), via the company's website, or a 24-hour hotline, with pricing published at PHP 75/day for combined cord blood and cord stem cell banking on instalment plans of 3, 6, 9, or 12 months and a long-term storage commitment of up to 21 years. Bundled into enrolment is the StemCord Bonus Covers suite of medical insurance-style add-ons covering transplant expenses, alternative stem cell sourcing, HLA testing, continuity of storage until age 21, and international courier charges. As of 2017 over 40,000 cord blood units had been stored with the company, and growth in stored inventory is implied by five consecutive NetCord-FACT accreditations (2011, 2014, 2017, 2021, 2026) and ongoing regional sales coverage in Metro Manila and Jakarta.

Distribution and patient education rely on a mix of field sales consultants, regional offices in Singapore, Manila, and Jakarta, an in-person presence at pregnancy expos, free pregnancy webinars (launched 2020, first session drew 1,000+ attendees), brand collaborations with parenting-product partners, and a content/blog library on the company website. The company employs 11-50 people across Singapore, the Philippines, and Indonesia; carries a Singapore Ministry of Health cord-blood banking licence; and complies with Singapore's Personal Data Protection Act. Revenue figures are not publicly disclosed, and no external funding rounds, acquisitions, or AI/ML product capabilities are evidenced in the source data.

Short descriptiontext

StemCord is a Singapore-headquartered private cord blood bank founded in 2002 that collects, processes, and cryopreserves umbilical cord blood and cultured cord stem cells for expectant-parent subscribers across Singapore, the Philippines, and Indonesia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersQuezon City, Philippines
HQ citystring
Quezon City
HQ countrystring
Philippines
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cord blood banking, stem cell banking, umbilical cord preservation, cryopreservation services, biological insurance
Industry3 codes
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cord Blood Banking Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Cord Blood Banking Services
TypeSubscription Recurring
Description

Private cord blood banking services including enrollment, collection kit, laboratory processing, maternal blood testing, viability testing, and storage. Services are provided on a long-term commitment basis with payment plans available.

stemcord.com.ph
2Cord Stem Cells Banking
TypeSubscription Recurring
Description

Banking of Mesenchymal Stem Cells (MSCs) cultured from umbilical cord tissue, processed using CultureFIRST method and stored alongside cord blood.

stemcord.com.ph
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Cord Blood Banking from ₱75/day
ModelSubscriptionBilling cadenceAnnual
Notes

Cord blood banking starts from as little as ₱75 per day (PHP). Storage commitment is a long-term commitment of up to 21 years. Initial fees cover enrollment, collection, processing, and first year of storage, followed by annual renewal fees.

stemcord.com.ph
2Cord Blood and Cord Stem Cells Combined Banking
ModelSubscriptionBilling cadenceMonthly
Notes

Combined banking of both cord blood (Haemopoietic Stem Cells) and cord stem cells (Mesenchymal Stem Cells) starts from ₱75 per day. Payment options include credit cards through PayPal, and installment plans of 3/6/9/12 months.

stemcord.com.ph
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1CultureFIRST
Description

StemCord's proprietary process that cultures cord stem cells before storage, providing 8x more cell yield than frozen tissue storage.

stemcord.com.ph
+1 more record
Core offering1 text field

StemCord is an autologous, private cord blood bank that collects, processes, and cryopreserves umbilical cord blood containing Haematopoietic Stem Cells (HSCs) and umbilical cord tissue-derived Mesenchymal Stem Cells (MSCs) for long-term family storage. The company provides enrollment, collection kits, laboratory processing, maternal blood testing, viability testing, and multi-location cryogenic storage at -180°C or colder using its proprietary CultureFIRST method and dual-bag dual-site storage architecture.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 8x higher cell yield with CultureFIRST compared to frozen cord tissue extraction
+2 more records
Product overview1 text field

StemCord offers a private cord blood and cord stem cells banking service headquartered in Singapore with operations in the Philippines and Indonesia. The core offering consists of two integrated banking services: Cord Blood Banking for Haemopoietic Stem Cells (HSCs) and Cord Stem Cells Banking for Mesenchymal Stem Cells (MSCs). The proprietary CultureFIRST processing method cultures stem cells before storage to maximize yield. Storage is provided in two bags at two separate Singapore locations for security. Comprehensive insurance coverage (StemCord Bonus Covers) is included with enrollment, covering transplant expenses, medical testing, and international courier services. Pricing starts at PHP 75/day with flexible payment plans.

Product and service4 records
1Cord Blood Banking
CategoryCord Blood Banking
Description

Private cord blood banking service that collects, processes, and stores Haemopoietic Stem Cells (HSCs) from umbilical cord blood for expectant parents and families. HSCs are used to treat over 80 diseases including blood cancers, bone marrow disorders, and immune deficiencies.

2Cord Stem Cells Banking
CategoryStem Cell Banking
Description

Banking service for Mesenchymal Stem Cells (MSCs) extracted and cultured from umbilical cord tissue (Wharton's Jelly) for expectant parents and families. MSCs have regenerative potential for treating conditions such as heart disease, diabetes, spinal cord injuries, and autoimmune disorders.

3StemCord Bonus Covers
CategoryInsurance Add-on Packages
Description

Suite of medical insurance packages bundled with enrollment: QualityPLUS (alternative stem cell source expenses), Transplant Medicare (autologous transplant medical expenses), AssuredPlus (HLA testing and viability assays), Care21 (storage coverage until child turns 21 if parent passes), and WorldWidePlus (international courier charges).

4Enrollment and Collection Kit
CategoryEnrollment Services
Description

Complete enrollment process including contract signing, receipt of cord blood/cord stem cells collection kit, and payment processing. The collection kit contains all materials required for hospital cord blood collection immediately after delivery.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US private cord blood and cord tissue bank owned by Revvity (formerly PerkinElmer). Comparable end-to-end autologous banking service with established brand and physician channel — benchmark for mature-market positioning.

TypeBroad incumbent
Description

US-listed private cord blood bank with international licensee network. Comparable autologous banking model and provides a public benchmark for valuation and unit economics in the cord blood banking category.

TypeBroad incumbent
Description

Largest US private newborn stem cell company, part of the Cooper Companies portfolio. Offers private cord blood and cord tissue banking with extensive consumer marketing — useful comparable for scale, product packaging and pricing benchmarks.

4China Cord Blood Corporation
TypeBroad incumbent
Description

One of the largest cord blood banking operators in China, listed in New York. Operates a multi-province network of licensed cord blood banks — broad incumbent in cord blood storage, demonstrating scaled economics StemCord has not yet reached.

TypeRegional player
Description

UK-based private stem cell bank with international presence. Comparable autologous cord blood and cord tissue banking offering — relevant comp for service packaging, insurance add-ons and cross-border distribution patterns.

6Singapore Cord Blood Bank
TypeEmerging player
Description

Singapore-based public cord blood bank (non-profit). Comparable storage operations and laboratory capabilities but offers donated public banking rather than autologous storage — a substitute for cost-sensitive expectant parents considering StemCord.

TypeDirect peer
Description

Malaysian private cord blood bank providing collection, processing and long-term storage of umbilical cord blood. Comparable service offering, similar regulatory environment and overlapping target customer segment of expectant parents in the region.

8Cellsafe International
TypeRegional player
Description

Indonesia-focused private stem cell and cord blood bank. Comparable autologous cord blood and MSC banking services but concentrated in Indonesia, overlapping directly with StemCord's PT StemCord Indonesia Sehat operations.

TypeDirect peer
Description

Malaysian private cord blood and cord tissue bank offering HSC and MSC cryopreservation services. Closely comparable business model (private family banking, multi-product offering, regional Southeast Asia distribution) competing in adjacent geography.

TypeDirect peer
Description

SGX-listed private cord blood banking group headquartered in Singapore with regional operations across Asia. Direct competitor offering autologous and family cord blood banking with similar FACT-Netcord-aligned positioning and overlapping customer base of expectant parents in Southeast Asia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StemCord

Cord Blood Banking Servicesstemcord.com.ph

StemCord is a Singapore-headquartered private cord blood bank founded in 2002 that collects, processes, and cryopreserves umbilical cord blood and cultured cord stem cells for expectant-parent subscribers across Singapore, the Philippines, and Indonesia.

What StemCord does

StemCord is a privately-held, autologous cord blood bank incorporated in March 2002 and headquartered in Singapore, with regional operations in the Philippines (opened 2020) and Indonesia. It collects, processes, and cryopreserves umbilical cord blood containing haemopoietic stem cells (HSCs) and, since the 2015 Stem Med partnership, mesenchymal stem cells (MSCs) cultured from cord tissue using its proprietary CultureFIRST method, which the company claims yields approximately 8x more viable cells than traditional frozen-tissue extraction. Samples are processed in an ISO Class 5 clean room, coded under the ISBT 128 standard, and stored in vapour-phase liquid nitrogen at -180 deg C or colder across two separate cryo bags at two distinct laboratory locations in Singapore. The company was founded and is led by practising haematologists, medical oncologists, and a nephrologist with direct bone-marrow and stem-cell transplantation programme experience at Singapore General Hospital and National University Hospital.

The commercial model is direct-to-consumer, targeting expectant parents in the third trimester of pregnancy (around 28-32 weeks). Customers enrol through sales consultants at baby and parenting fairs (e.g. Momzilla Fair, Edamama New Mama Expo), via the company's website, or a 24-hour hotline, with pricing published at PHP 75/day for combined cord blood and cord stem cell banking on instalment plans of 3, 6, 9, or 12 months and a long-term storage commitment of up to 21 years. Bundled into enrolment is the StemCord Bonus Covers suite of medical insurance-style add-ons covering transplant expenses, alternative stem cell sourcing, HLA testing, continuity of storage until age 21, and international courier charges. As of 2017 over 40,000 cord blood units had been stored with the company, and growth in stored inventory is implied by five consecutive NetCord-FACT accreditations (2011, 2014, 2017, 2021, 2026) and ongoing regional sales coverage in Metro Manila and Jakarta.

Distribution and patient education rely on a mix of field sales consultants, regional offices in Singapore, Manila, and Jakarta, an in-person presence at pregnancy expos, free pregnancy webinars (launched 2020, first session drew 1,000+ attendees), brand collaborations with parenting-product partners, and a content/blog library on the company website. The company employs 11-50 people across Singapore, the Philippines, and Indonesia; carries a Singapore Ministry of Health cord-blood banking licence; and complies with Singapore's Personal Data Protection Act. Revenue figures are not publicly disclosed, and no external funding rounds, acquisitions, or AI/ML product capabilities are evidenced in the source data.

StemCord firmographics

Firmographics
Name
StemCord
Legal name
STEMCORD SG PHILS. CORPORATION
Website
https://stemcord.com.ph
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
StemCord is a Singapore-headquartered private cord blood bank founded in 2002 that collects, processes, and cryopreserves umbilical cord blood and cultured cord stem cells for expectant-parent subscribers across Singapore, the Philippines, and Indonesia.
Ownership category
akta.pro rank

StemCord industry classification

Industry
Product category
Cord Blood Banking Services
NAICS
Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cord blood banking
  • Stem cell banking
  • Umbilical cord preservation
  • Cryopreservation services
  • Biological insurance

Where StemCord is headquartered

Location

Headquarters

HQ city
Quezon City
HQ country
Philippines
HQ region
Asia

Offices3 records

Markets served

StemCord business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Cord Blood Banking Services: Private cord blood banking services including enrollment, collection kit, laboratory processing, maternal blood testing, viability testing, and storage. Services are provided on a long-term commitment basis with payment plans available.
  2. Cord Stem Cells Banking: Banking of Mesenchymal Stem Cells (MSCs) cultured from umbilical cord tissue, processed using CultureFIRST method and stored alongside cord blood.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCord Blood Banking from ₱75/day
SubscriptionMonthlyCord Blood and Cord Stem Cells Combined Banking

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

StemCord product offering

Product offering

Core offering

StemCord is an autologous, private cord blood bank that collects, processes, and cryopreserves umbilical cord blood containing Haematopoietic Stem Cells (HSCs) and umbilical cord tissue-derived Mesenchymal Stem Cells (MSCs) for long-term family storage. The company provides enrollment, collection kits, laboratory processing, maternal blood testing, viability testing, and multi-location cryogenic storage at -180°C or colder using its proprietary CultureFIRST method and dual-bag dual-site storage architecture.

Product overview

StemCord offers a private cord blood and cord stem cells banking service headquartered in Singapore with operations in the Philippines and Indonesia. The core offering consists of two integrated banking services: Cord Blood Banking for Haemopoietic Stem Cells (HSCs) and Cord Stem Cells Banking for Mesenchymal Stem Cells (MSCs). The proprietary CultureFIRST processing method cultures stem cells before storage to maximize yield. Storage is provided in two bags at two separate Singapore locations for security. Comprehensive insurance coverage (StemCord Bonus Covers) is included with enrollment, covering transplant expenses, medical testing, and international courier services. Pricing starts at PHP 75/day with flexible payment plans.

Differentiator

Problem solved

Functional benefit

Brands

  • CultureFIRST: StemCord's proprietary process that cultures cord stem cells before storage, providing 8x more cell yield than frozen tissue storage.
  • StemCord Bonus Covers

Products and services

  • Cord Blood Banking Private cord blood banking service that collects, processes, and stores Haemopoietic Stem Cells (HSCs) from umbilical cord blood for expectant parents and families. HSCs are used to treat over 80 diseases including blood cancers, bone marrow disorders, and immune deficiencies.
  • Cord Stem Cells Banking Banking service for Mesenchymal Stem Cells (MSCs) extracted and cultured from umbilical cord tissue (Wharton's Jelly) for expectant parents and families. MSCs have regenerative potential for treating conditions such as heart disease, diabetes, spinal cord injuries, and autoimmune disorders.
  • StemCord Bonus Covers Suite of medical insurance packages bundled with enrollment: QualityPLUS (alternative stem cell source expenses), Transplant Medicare (autologous transplant medical expenses), AssuredPlus (HLA testing and viability assays), Care21 (storage coverage until child turns 21 if parent passes), and WorldWidePlus (international courier charges).
  • Enrollment and Collection Kit Complete enrollment process including contract signing, receipt of cord blood/cord stem cells collection kit, and payment processing. The collection kit contains all materials required for hospital cord blood collection immediately after delivery.

Quantifiable outcome

  • 8x higher cell yield with CultureFIRST compared to frozen cord tissue extraction
  • +2 more outcomes

Companies that use StemCord

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

StemCord technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

StemCord partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

StemCord competitors and assessment

Company assessment

Broad incumbents

  • ViaCord: US private cord blood and cord tissue bank owned by Revvity (formerly PerkinElmer). Comparable end-to-end autologous banking service with established brand and physician channel — benchmark for mature-market positioning.
  • Cryo-Cell International: US-listed private cord blood bank with international licensee network. Comparable autologous banking model and provides a public benchmark for valuation and unit economics in the cord blood banking category.
  • Cord Blood Registry (CBR): Largest US private newborn stem cell company, part of the Cooper Companies portfolio. Offers private cord blood and cord tissue banking with extensive consumer marketing — useful comparable for scale, product packaging and pricing benchmarks.
  • China Cord Blood Corporation: One of the largest cord blood banking operators in China, listed in New York. Operates a multi-province network of licensed cord blood banks — broad incumbent in cord blood storage, demonstrating scaled economics StemCord has not yet reached.

Regional players

  • Smart Cells International: UK-based private stem cell bank with international presence. Comparable autologous cord blood and cord tissue banking offering — relevant comp for service packaging, insurance add-ons and cross-border distribution patterns.
  • Cellsafe International: Indonesia-focused private stem cell and cord blood bank. Comparable autologous cord blood and MSC banking services but concentrated in Indonesia, overlapping directly with StemCord's PT StemCord Indonesia Sehat operations.

Emerging players

  • Singapore Cord Blood Bank: Singapore-based public cord blood bank (non-profit). Comparable storage operations and laboratory capabilities but offers donated public banking rather than autologous storage — a substitute for cost-sensitive expectant parents considering StemCord.

Direct peers

  • Stemlife Berhad: Malaysian private cord blood bank providing collection, processing and long-term storage of umbilical cord blood. Comparable service offering, similar regulatory environment and overlapping target customer segment of expectant parents in the region.
  • CryoCord: Malaysian private cord blood and cord tissue bank offering HSC and MSC cryopreservation services. Closely comparable business model (private family banking, multi-product offering, regional Southeast Asia distribution) competing in adjacent geography.
  • Cordlife Group: SGX-listed private cord blood banking group headquartered in Singapore with regional operations across Asia. Direct competitor offering autologous and family cord blood banking with similar FACT-Netcord-aligned positioning and overlapping customer base of expectant parents in Southeast Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

StemCord social profiles

Digital presence

StemCord compliance and trust

Trust signal

Compliance5 records

StemCord financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StemCord leadership team

Management profile

Number of profiles

Profiles5 records

StemCord subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

StemCord funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StemCord M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemCord

What does StemCord do?

StemCord is an autologous, private cord blood bank that collects, processes, and cryopreserves umbilical cord blood containing Haematopoietic Stem Cells (HSCs) and umbilical cord tissue-derived Mesenchymal Stem Cells (MSCs) for long-term family storage. The company provides enrollment, collection kits, laboratory processing, maternal blood testing, viability testing, and multi-location cryogenic storage at -180°C or colder using its proprietary CultureFIRST method and dual-bag dual-site storage architecture.

Is StemCord a public or private company?

StemCord is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was StemCord founded?

StemCord was founded in 2002. It employs 11 to 50 people.

Where is StemCord based?

StemCord is headquartered in Quezon City, Philippines, in the Asia region.

How does StemCord make money?

Two revenue lines are on record. Cord Blood Banking Services are the primary driver. The others are cord Stem Cells Banking.

Who are StemCord's main competitors?

Broad incumbents on record are ViaCord, Cryo-Cell International, Cord Blood Registry (CBR) and China Cord Blood Corporation. Regional players are Smart Cells International and Cellsafe International. Singapore Cord Blood Bank is listed as an emerging player. Direct peers are Stemlife Berhad, CryoCord and Cordlife Group.

Does StemCord have an API?

No public API is recorded for StemCord.

What industry is StemCord in?

StemCord's product category is Cord Blood Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 621991 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales